TRITONS

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Sep 12, 2024 → Oct 23, 2026

Cited window

Jul 3, 2025 → Oct 23, 2026

Retrieved

Oct 30, 2026

Title

Total RadIoTherapy of Oligometastatic caNcerS (TRITONS)

Registry

NCT06587490

Study IDs

810616

Sponsor

University of California, San Diego

Design

Phase 3 · Interventional, randomized, parallel

Status

Recruiting

Enrollment

300 estimated

Registered

2024-09-19

Start

2024-11-12 actual

Primary completion

2033-11 estimated

Primary endpoint

Progression-Free Survival (PFS)

Interventions

1 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –The source search did not run to completion, so some matching discussion may be missing.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –19 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed for this edition are selected public discussions, not a representative survey. Some relevant passages were not fully assessed, and unnamed or differently worded references to the trial may be missing.
• –No TRITONS efficacy or toxicity results are provided. The October 2026 publication discussion concerns a protocol announcement and linked article information, not a results report or a complete protocol assessment.
• –Several discussions concern separate settings, including de novo oligometastatic hormone-sensitive prostate cancer, oligoprogressive disease and colorectal-cancer surgery. Their interpretations cannot be treated as TRITONS outcomes or validated selection rules for its entire population.
• –A speaker's statements about the talk are relays rather than a direct transcript of its presenter. Another speaker's principal-investigator involvement is described by the source and should not be treated as an independently established role or an external appraisal.
• –Reposts and relays do not establish additional independent HCP agreement. The nature of a speaker's disclosed interest in the prognostic test remains unclear.

How reports are built and checked: Methods.

Last checked for new commentary Oct 30, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "TRITONS" (NCT06587490), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "tritons-06587490". If you cannot make requests, read https://www.erudio.com/reports/tritons-nct06587490.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT06587490", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct06587490 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/tritons-nct06587490.json
curl https://www.erudio.com/reports/tritons-nct06587490.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "tritons-06587490" })